GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Piramal Pharma Ltd (NSE:PPLPHARMA) » Definitions » Operating Margin %

Piramal Pharma (NSE:PPLPHARMA) Operating Margin % : 11.55% (As of Mar. 2025)


View and export this data going back to 2022. Start your Free Trial

What is Piramal Pharma Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Piramal Pharma's Operating Income for the three months ended in Mar. 2025 was ₹3,182 Mil. Piramal Pharma's Revenue for the three months ended in Mar. 2025 was ₹27,541 Mil. Therefore, Piramal Pharma's Operating Margin % for the quarter that ended in Mar. 2025 was 11.55%.

The historical rank and industry rank for Piramal Pharma's Operating Margin % or its related term are showing as below:

NSE:PPLPHARMA' s Operating Margin % Range Over the Past 10 Years
Min: -0.68   Med: 5.61   Max: 6.87
Current: 6.87


NSE:PPLPHARMA's Operating Margin % is ranked worse than
50.05% of 973 companies
in the Drug Manufacturers industry
Industry Median: 6.87 vs NSE:PPLPHARMA: 6.87

Piramal Pharma's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Piramal Pharma's Operating Income for the three months ended in Mar. 2025 was ₹3,182 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2025 was ₹6,285 Mil.


Piramal Pharma Operating Margin % Historical Data

The historical data trend for Piramal Pharma's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Piramal Pharma Operating Margin % Chart

Piramal Pharma Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25
Operating Margin %
- 5.64 -0.68 5.58 6.87

Piramal Pharma Quarterly Data
Mar21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.08 1.02 6.66 6.39 11.55

Competitive Comparison of Piramal Pharma's Operating Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Piramal Pharma's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Piramal Pharma's Operating Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Piramal Pharma's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Piramal Pharma's Operating Margin % falls into.


;
;

Piramal Pharma Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Piramal Pharma's Operating Margin % for the fiscal year that ended in Mar. 2025 is calculated as

Operating Margin %=Operating Income (A: Mar. 2025 ) / Revenue (A: Mar. 2025 )
=6284.9 / 91511.8
=6.87 %

Piramal Pharma's Operating Margin % for the quarter that ended in Mar. 2025 is calculated as

Operating Margin %=Operating Income (Q: Mar. 2025 ) / Revenue (Q: Mar. 2025 )
=3182.3 / 27540.7
=11.55 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Piramal Pharma  (NSE:PPLPHARMA) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Piramal Pharma Operating Margin % Related Terms

Thank you for viewing the detailed overview of Piramal Pharma's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Piramal Pharma Business Description

Traded in Other Exchanges
Address
Kamani Junction, LBS Marg, Ground Floor, Piramal Ananta, Agastya Corporate Park, Opposite Fire Brigade, Kurla (West), Mumbai, MH, IND, 400070
Piramal Pharma Ltd is a pharmaceutical company, providing end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and international distribution network. It operates under three business verticals; an integrated contract development and manufacturing (CDMO) business providing Active pharmaceutical ingredients (APIs), Finished dosage forms (FDFs), biologics, and vaccines among other products; the other two business verticals include a complex hospital generics business, and an India consumer healthcare business, selling over-the-counter products in India. Geographically, the company generates maximum revenue from North America and the rest from Europe, India, Japan, and other markets.

Piramal Pharma Headlines

No Headlines